Theragent and CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy

ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ — Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax Therapeutics Inc. This past week, Theragent produced the…